Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 43

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 43
---
 Act and other SEC and national exchange requirements will increase
our costs and require additional management resources. We recently have begun upgrading our procedures and controls and will need to
continue to implement additional procedures and controls as we grow our business and organization and to satisfy new reporting requirements.
If we are unable to complete the required assessment as to the adequacy of our internal control over financial reporting, as required
by Section 404 of the Sarbanes-Oxley Act or if we fail to maintain internal control over financial reporting, our ability to produce
timely, accurate and reliable periodic financial statements could be impaired.

If we do not maintain adequate internal control
over financial reporting, investors could lose confidence in the accuracy of our periodic reports filed under the Exchange Act. Additionally,
our ability to obtain additional financing could be impaired or a lack of investor confidence in the reliability and accuracy of our
public reporting could cause our stock price to decline.

The market price for our Common Stock may be particularly volatile given our status as a relatively unknown company, with a lack of profits, which could lead to wide fluctuations in our share price. You may be unable to sell your Common Stock at or above your purchase price, which may result in substantial losses to you.

The price of our Common Stock in the future may
be particularly volatile when compared to the shares of larger, more established public companies that trade on a national securities
exchange and have large public floats. The volatility in our share price will be attributable to a number of factors. First, our Common
Stock will be, compared to the shares of such larger, more established companies, sporadically and thinly traded. As a consequence of
this limited liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the
price of those shares in either direction. The price of our shares could decline precipitously in the event that a large number of our
Common Stock are sold on the market without commensurate demand. Secondly, we are a speculative or “risky” investment due
to our lack of profits to date, and uncertainty of future market acceptance for our products. As a consequence of this enhanced risk,
more risk-adverse investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress,
be more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of a
larger, more established company that trades on a national securities exchange and has a large